Skip to main content

Drug Interactions between atazanavir and emtricitabine / nelfinavir / tenofovir disoproxil

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nelfinavir atazanavir

Applies to: emtricitabine / nelfinavir / tenofovir disoproxil and atazanavir

Nelfinavir may increase the blood levels and effects of atazanavir. This may increase the risk and/or severity of side effects such as jaundice, kidney stones, gallstones, high blood sugar, diabetes, and irregular heartbeat. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you develop yellowing of the skin or eyes, pain in your side or lower back, painful urination, blood in your urine, abdominal pain or tenderness, or sudden dizziness, lightheadedness, fainting, or a slow heart rate during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

tenofovir atazanavir

Applies to: emtricitabine / nelfinavir / tenofovir disoproxil and atazanavir

Using tenofovir together with atazanavir may alter the blood levels and effects of both drugs. Using these medications together may cause atazanavir to be less effective and increase the blood levels and effects of tenofovir. Contact your doctor if your condition changes or if you experience increased side effects such as kidney problems. Your doctor may be able to prescribe alternatives that do not interact or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Moderate

atazanavir food

Applies to: atazanavir

Food can enhance the levels of atazanavir in your body. To ensure maximal oral absorption, atazanavir should be administered with or immediately after a meal. This will make it easier for your body to absorb the medication.

Minor

tenofovir food

Applies to: emtricitabine / nelfinavir / tenofovir disoproxil

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Protease inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'protease inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'protease inhibitors' category:

  • atazanavir
  • emtricitabine/nelfinavir/tenofovir disoproxil

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.